Supernus Pharmaceuticals
SUPN
#4296
Rank
C$2.81 B
Marketcap
$50.90
Share price
0.55%
Change (1 day)
41.04%
Change (1 year)

P/E ratio for Supernus Pharmaceuticals (SUPN)

P/E ratio as of November 2024 (TTM): 45.6

According to Supernus Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 45.6329. At the end of 2022 the company had a P/E ratio of 31.6.

P/E ratio history for Supernus Pharmaceuticals from 2012 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202231.610.42%
202128.6173.84%
202010.4-5.37%
201911.0-28.93%
201815.5-55.98%
201735.3156.98%
201613.7-70.39%
201546.3-245.18%
2014-31.91136.28%
2013-2.58-24.59%
2012-3.42

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-6.56-114.37%๐Ÿ‡บ๐Ÿ‡ธ USA
21.5-52.87%๐Ÿ‡บ๐Ÿ‡ธ USA
154 238.45%๐Ÿ‡บ๐Ÿ‡ธ USA
13.7-70.05%๐Ÿ‡บ๐Ÿ‡ธ USA
39.3-13.88%๐Ÿ‡บ๐Ÿ‡ธ USA
11.1-75.72%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.